PEG-IFN riba in order of $20,000 for a course
telaprevir and presumably boceprevir in order of $50,000 for a course
the latter have probably set the benchmark for future pricings
HIV is the very interesting area as the viral loads are lower, and the theoretical 10-fold reduction of BIT225 from ape studies is more significant. It remains to be seen what the effect on macrophages has on disease course.
victrelis approved in austr, page-6
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.002(7.14%) |
Mkt cap ! $23.46M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $51.84K | 1.992M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 198646 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 199924 | 1 |
View Market Depth
| Last trade - 15.36pm 30/08/2024 (20 minute delay) ? |
| BIT (ASX) Chart |